page contents
  • Anne

May 2022 Update!

Enhertu, which has shown statistically significant improvement in PFS when compared with Kadcyla (TDM1) as second-line treatment for HER2-positive MBC, has now been FDA-approved for HER2 positive adult patients who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. At a median follow-up of about 16 months in the DESTINY-Breast03 Phase 3 study, median Progression Free Survival was not reached with Enhertu and was 6.8 months with T-DM1. The benefit was observed across all prespecified subgroups, including patients with brain metastases. From:

104 views0 comments

Recent Posts

See All

Enhertu has already been approved for HER2 positive MBC patients who relapsed on prior treatment, and is being assessed for HER2 low patients. HR+, HER2- and TNBC patients have either HER2 low express

An Experimental Drug Called Elacestrant May be FDA-Approved This Year! Possibly the most pivotal news divulged at the San Antonio Breast Cancer Symposium in Dec. 2021 was a study of an endocrine ther